Methods of using pd-l1 expression in treatment decisions for cancer therapy
AssigneeCreatv MicroTech, Inc.
InventorsDaniel ADAMS, Cha-Mei TANG
Life of this patent
Estimating the term…
Abstract
Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.
Claims18
A method of predicting responsiveness of a subject having cancer to treatment with an immune checkpoint inhibitor, comprising:
- assaying cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs), and optionally one or more of epithelial to mesenchymal transition CTCs (EMTCTCs), and cancer associated vascular endothelial cells (CAVEs), isolated from a subject having cancer for PD-L1 expression,
- wherein when PD-L1 expression is detected, the subject is predicted to be responsive to treatment with an immune checkpoint inhibitor.
A method of screening a subject having cancer for susceptibility to an immune checkpoint inhibitor, comprising:
- assaying CAMLs and CTCs, and optionally one or more of EMTCTCs and CAVEs, isolated from a subject having cancer for PD-L1 expression,
- wherein when PD-L1 expression is detected, the subject is deemed susceptible to an immune checkpoint inhibitor.
A method for identifying a subject having cancer to receive an immune checkpoint inhibitor treatment, comprising:
- assaying CAMLs and CTCs, and optionally one or more of EMTCTCs and CAVEs, isolated from a subject having cancer for PD-L1 expression,
- wherein when PD-L1 expression is detected, the subject is identified as a subject to receive an immune checkpoint inhibitor treatment.
Dependencies are inferred from the claim text.